title: OLIG2 over-expression impairs proliferation of human Down syndrome neural progenitors.
abstract: Mental retardation and early Alzheimer's disease (AD) have generally been attributed to progressive neuronal loss in the developing and mature Down syndrome (DS) brain. However, reduced neuronal production during development could also contribute to the smaller brain size and simplified gyral patterning seen in this disorder. Here, we show impairments in proliferation within the ventricular zone (VZ) of early DS fetal cortex and in cultured early passage DS human neural progenitors (HNPs). We find that the reduced proliferative rates correspond temporally with increased expression of the chromosome 21 (HSA21) associated, oligodendrocyte transcription factor OLIG2 at 14-18 weeks gestational age (GA) (period of neurogenesis). Moreover, the DS HNPs adopt more oligodendrocyte-specific features including increased oligodendrocyte marker expression, as well as a reduction in KCNA3 potassium channel expression and function. We further show that OLIG2 inhibition or over-expression regulates potassium channel expression levels and that activation or inhibition of these channels influences the rate of progenitor proliferation. Finally, neural progenitors from Olig2 over-expressing transgenic mice exhibit these same impairments in proliferation and potassium channel expression. These findings suggest that OLIG2 over-expression inhibits neural progenitor proliferation through changes in potassium channel activity, thereby contributing to the reduced neuronal numbers and brain size in DS.
authors.affiliation: Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA.
authors.forename: Jie
authors.initials: J
authors.lastname: Lu
authors.forename: Gewei
authors.initials: G
authors.lastname: Lian
authors.forename: Hui
authors.initials: H
authors.lastname: Zhou
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Esposito
authors.forename: Luca
authors.initials: L
authors.lastname: Steardo
authors.forename: Laurent C
authors.initials: LC
authors.lastname: Delli-Bovi
authors.forename: Jonathan L
authors.initials: JL
authors.lastname: Hecht
authors.forename: Q Richard
authors.initials: QR
authors.lastname: Lu
authors.forename: Volney
authors.initials: V
authors.lastname: Sheen
mesh_terms: D000818:Animals; D051792:Basic Helix-Loop-Helix Proteins / Q000235:genetics* / Q000378:metabolism; D002454:Cell Differentiation; D049109:Cell Proliferation; D004314:Down Syndrome / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D015870:Gene Expression; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D009419:Nerve Tissue Proteins / Q000235:genetics* / Q000378:metabolism; D058953:Neural Stem Cells / Q000378:metabolism / Q000473:pathology*; D055495:Neurogenesis; D009474:Neurons / Q000378:metabolism / Q000473:pathology*; D000076104:Oligodendrocyte Transcription Factor 2
chemical_list: D051792:Basic Helix-Loop-Helix Proteins; D009419:Nerve Tissue Proteins; D000076104:Oligodendrocyte Transcription Factor 2; C405708:OLIG2 protein, human